Skip to Main Content


Chapter 61. Glaucoma

The preferred treatment option for a 67-year-old man with primary open-angle glaucoma (POAG), no significant past medical history (PMH), and allergy to benzalkonium chloride is:

A. Tafluprost

B. Latanoprost

C. Brinzolamide

D. Carbachol

E. Levobunolol

An appropriate counseling statements for timolol is:

A. This medication has no significant systemic effects.

B. This medication may cause mydriasis.

C. Do not use this medication if you are allergic to sulfonamides.

D. This medication may cause an increase in iris pigmentation.

E. This medication may cause bradycardia.

All of the following characteristics would increase a patient’s risk of developing primary angle-closure glaucoma except:

A. Myopia

B. Female gender

C. Shallow anterior chamber

D. Central corneal thickness of 560 μm

E. Asian descent

The following drug would be contraindicated in a patient with with primary open-angle glaucoma (POAG) and allergy to sulfonamides:

A. Travoprost

B. Betaxolol

C. Brinzolamide

D. Pilocarpine

The following drug has little clinically significant systemic adverse effects:

A. Bimatoprost

B. Brimonidine

C. Carteolol

D. Acetazolamide

E. Apraclonidine

The following drug may darken pigmentation of the iris:

A. Tafluprost

B. Carteolol

C. Brinzolamide

D. Pilocarpine

E. Levobunolol

The following medications are likely to increase IOP in a patient with primary angle-closure glaucoma (PACG) except:

A. Diphenhydramine

B. Amitriptyline

C. Pseudoephedrine


Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.